血小板与肝硬化相关性研究进展

摘要/Abstract

摘要： 肝硬化代表了慢性肝病的终末期阶段,其特征为肝脏出现广泛的纤维化、假小叶形成以及肝内外血管异常增生,此类病症患者通常会出现血小板计数降低及功能障碍的现象。近年来,血小板与肝硬化相关性研究逐渐增多,其被认为在肝硬化病情进展、出血事件及预后中有着重要的作用,本文将对血小板与肝硬化相关性的研究进展进行综述。

关键词: 血小板, 肝硬化, 出血事件, 病情严重程度, 预后

刘佩, 郑盛, 杨涓. 血小板与肝硬化相关性研究进展[J]. 肝脏, 2025, 30(6): 881-885.

/ 推荐

[1] Ginès P, Krag A, Abraldes J G, et al. Liver cirrhosis[J]. Lancet, 2021, 398(10308): 1359-1376.
[2] Roberts LN, Lisman T, Stanworth S, et al. Periprocedural management of abnormal coagulation parameters and thrombocytopenia in patients with cirrhosis: Guidance from the SSC of the ISTH[J]. J Thromb Haemost, 2022, 20(1): 39-47.
[3] Jurk K, Kehrel B E. Platelets: physiology and biochemistry[J]. Semin Thromb Hemost, 2024, 50(05): 794-803.
[4] Liang C, Takahashi K, Furuya K, et al. Dualistic role of platelets in living donor liver transplantation: are they harmful? [J]. World J Gastroenterol, 2022, 28(9): 897-908.
[5] Li J, Karakas D, Xue F, et al. Desialylated platelet clearance in the liver is a novel mechanism of systemic immunosuppression [J]. Research, 2023, 6: 0236.
[6] Sun Y, Tong H, Chu X, et al. Notch1 regulates hepatic thrombopoietin production[J]. Blood, 2024, 143(26): 2778-2790.
[7] Michalopoulos G K, Bhushan B. Liver regeneration: biological and pathological mechanisms and implications[J]. Nat Rev Gastroenterol Hepatol, 2021, 18(1): 40-55.
[8] Yagi S, Hirata M, Miyachi Y, et al. Liver regeneration after hepatectomy and partial liver transplantation[J]. Int J Mol Sci, 2020, 21(21): 8414.
[9] Meyer J, Balaphas A, Fontana P, et al. Platelet interactions with liver sinusoidal endothelial cells and hepatic stellate cells lead to hepatocyte proliferation[J]. Cells, 2020 ,9(5):1243.
[10] Takahashi K, Liang C, Oda T, et al. Platelet and liver regeneration after liver surgery[J]. Surg Today, 2020, 50(9): 974-983.
[11] Czajka P, Przybyłkowski A, Nowak A, et al. Antiplatelet drugs and liver fibrosis[J]. Platelets, 2022, 33(2): 219-228.
[12] 林勇, 曾欣, 胡平方. 中国肝硬化临床诊治共识意见[J]. 临床肝胆病杂志, 2023, 39(9): 2057-2073.
[13] Sepanlou S G, Safiri S, Bisignano C, et al. The global, regional, and national burden of cirrhosis by cause in 195 countries and territories, 1990-2017: a systematic analysis for the global burden of disease study 2017[J]. Lancet Gastroenterol Hepatol, 2020, 5(3): 245-266.
[14] 贺鸣,樊亚楠,巴证清,等. 肝硬化合并血小板减少症的相关因素分析:一项2517例患者的横断面研究[J]. 中华肝脏病杂志,2024,32(6):508-516.
[15] Fierro-Angulo O M, González-Regueiro J A, Pereira-García A, et al. Hematological abnormalities in liver cirrhosis[J]. World J Hepatol, 2024, 16(9): 1229-1246.
[16] Desai S, Subramanian A. Thrombocytopenia in chronic liver disease: challenges and treatment strategies[J]. Cureus, 2021, 13(7):e16342.
[17] Yoshida H, Shimizu T, Yoshioka M, et al. The role of the spleen in portal hypertension[J]. J Nippon Med Sch, 2023, 90(1): 20-25.
[18] Li J P, Tan Y, Sun H, et al. Clinical management of thrombocytopenia in cirrhosis[J]. Chinese journal of hepatology, 2024;32(6):489-492.
[19] Sigal S H, Sherman Z, Jesudian A. Clinical implications of thrombocytopenia for the cirrhotic patient[J]. Hepat Med, 2020, 12: 49-60.
[20] Satoh T, Takiguchi H, Uojima H, et al. B cell-activating factor is involved in thrombocytopenia in patients with liver cirrhosis[J]. Ann Hematol, 2022, 101(11): 2433-2444.
[21] Wang Z, Zhang A, Yin Y, et al. Clinical prediction of HBV-associated cirrhosis using machine learning based on platelet and bile acids[J]. Clin Chim Acta, 2023, 551: 117589.
[22] Ali S M, Farrukh S Z U I, Haqqi S A U H, et al. Oesophageal varices and associated factors in cirrhotic patients with hepatitis C[J]. J Ayub Med Coll Abbottabad, 2022, 34(4): 838-841.
[23] Fattah S A, El-Hamshary N K, Kilany Y F, et al. Prognostic and predictive values of meld score, platelet count and pre albumin in patients with compensated and decompensated liver cirrhosis with acute variceal bleeding[J]. J Egypt Soc Parasitol, 2012, 42(2): 443-452.
[24] Abdel Hammed M R, El-Amien H A, Asham M N, et al. Platelets indices and blood neutrophil to lymphocyte ratio be used as predictors for diagnosis of spontaneous bacterial peritonitis in decompensated post hepatitis liver cirrhosis?[J]. Egypt J Immunol, 2022;29(4):12-24.
[25] Termsinsuk P, Auesomwang C. Factors that predict recurrent spontaneous bacterial peritonitis in cirrhotic patients[J]. Int J Clin Pract, 2020, 74(3) e13457.
[26] 吴昆,张冬霞. 检测凝血功能和血小板计数对肝硬化患者的临床意义[J]. 中国实用医药,2017,12(17):58-59.
[27] 郭苒.血小板与凝血指标检测对肝硬化患者病情程度的评估价值[J].现代诊断与治疗,2020,31(03):440-441.
[28] Brusilovskaya K, Hofer B S, Simbrunner B, et al. Platelet function decreases with increasing severity of liver cirrhosis and portal hypertension—a prospective study[J]. Thromb Haemost, 2023,123(12):1140-1150.
[29] Liu H, Chen P, Jiang B, et al. The value of platelet parameters and related scoring system in predicting esophageal varices and collateral veins in patients with liver cirrhosis[J]. J Clin Lab Anal, 2021, 35(3): e23694.
[30] Kew G S, Chen Z J, Yip A W, et al. Identifying patients with cirrhosis who might avoid screening endoscopy based on serum albumin and bilirubin and platelet counts[J]. Clin Gastroenterol Hepatol, 2021, 19(1): 199-201.e2.
[31] Zanetto A, Campello E, Bulato C, et al. Increased platelet aggregation in patients with decompensated cirrhosis indicates higher risk of further decompensation and death[J]. J Hepatol, 2022, 77(3): 660-669.
[32] Hofer B S, Brusilovskaya K, Simbrunner B, et al. Decreased platelet activation predicts hepatic decompensation and mortality in patients with cirrhosis[J]. Hepatology, 2024, 80(5): 1120-1133.
[33] Larmann J, Handke J, Scholz A S, et al. Preoperative neutrophil to lymphocyte ratio and platelet to lymphocyte ratio are associated with major adverse cardiovascular and cerebrovascular events in coronary heart disease patients undergoing non-cardiac surgery[J]. BMC Cardiovasc Disord, 2020, 20(1): 230.
[34] Xu Q, Zhu C, Zhang Q, et al. Association between fibrinogen-to-albumin ratio and prognosis of patients with heart failure[J]. Eur J Clin Invest, 2023, 53(10): e14049.
[35] Yan C, Zhang W, Xiao Y, et al. The predictive role of the platelet-to-lymphocyte ratio for the risk of non-alcoholic fatty liver disease and cirrhosis: a nationwide cross-sectional study[J]. Front Endocrinol, 2024, 15: 1376894.
[36] Tudurachi B S, Anghel L, Tudurachi A, et al. Assessment of inflammatory hematological ratios (NLR, PLR, MLR, LMR and monocyte/HDL-cholesterol ratio) in acute myocardial infarction and particularities in young patients[J]. Int J Mol Sci, 2023, 24(18): 14378.
[37] Selvaggio S, Brugaletta G, Abate A, et al. Platelet to lymphocyte ratio, neutrophil to lymphocyte ratio and monocyte to HDL cholesterol ratio as helpful biomarkers for patients hospitalized for deep vein thrombosis[J]. Int J Mol Med, 2023, 51(6): 52.
[38] Takaya H, Namisaki T, Asada S, et al. ADAMTS13, VWF, and endotoxin are interrelated and associated with the severity of liver cirrhosis via hypercoagulability[J]. J Clin Med,2022, 11(7):1835.
[39] Albillos A, Martin-Mateos R, Van der Merwe S, et al. Cirrhosis-associated immune dysfunction[J]. Nat Rev Gastroenterol Hepatol, 2022,19(2):112-134.
[40] 贺燕燕, 刘一品. 瞬时弹性成像联合NLR、PLR对乙型肝炎肝硬化并发症的预测价值及与病情严重程度的关系[J]. 滨州医学院学报, 2021, 44(3): 167-172.
[41] 崔彦,李成浩.外周血相关指标与丙型肝炎肝硬化并发上消化道出血的相关性[J].延边大学医学学报,2023,46(4):271-275.
[42] Catanzaro R, Sciuto M, Lanzafame C, et al. Platelet to lymphocyte ratio as a predictive biomarker of liver fibrosis (on elastography) in patients with hepatitis C virus (HCV)-related liver disease[J]. Indian J Gastroenterol, 2020, 39(3):253-260.
[43] Wu J, Zhang X, Zhang X, et al. Correlation between platelet-to-neutrophil ratio and mortality in patients with HBV-associated decompensated cirrhosis[J]. Clin Lab, 2021, 67:10.7754
[44] Lichtman M A. Red cell distribution width as a bellwether of prognosis[J]. Blood Cells Mol Dis, 2024, 109: 102884.
[45] 赵小军.红细胞体积分布宽度与血小板比值在慢性乙型肝炎患者肝纤维化评估中的临床价值[J].检验医学与临床,2021,18(15):2278-2281.
[46] 杨娜,何华,赵天业,等.红细胞分布宽度/血小板比值、血小板/淋巴细胞比值、中性粒细胞/淋巴细胞比值对慢性丙型肝炎肝硬化代偿期的预测价值[J].临床肝胆病杂志,2021,37(6):1319-1325.
[47] Dallio M, Romeo M, Vaia P, et al. Red cell distribution width/platelet ratio estimates the 3-year risk of decompensation in metabolic dysfunction-associated steatotic liver disease-induced cirrhosis[J]. World J Gastroenterol, 2024, 30(7): 685-704.
[48] Zhu N, Shu H, Jiang W, et al. Mean platelet volume and mean platelet volume/platelet count ratio in nonvalvular atrial fibrillation stroke and large artery atherosclerosis stroke[J]. Medicine, 2020, 99(28): e21044.
[49] Ösken A, Hacı R, Dinç Asarcıklı L, et al. Mean platelet volume/platelet count ratio as a predictor of stent thrombosis in patients with ST-segment-elevation myocardial infarction[J]. Ir J Med Sci, 2021,190(3):1095-1102.
[50] 李映春,陈继梅,沈弢.平均血小板体积与血小板计数比率与HCV感染相关肝纤维化的相关性分析[J].中国病毒病杂志,2019, 9(1):6-11.
[51] Gozdas H T, Ince N. Elevated mean platelet volume to platelet ratio predicts advanced fibrosis in chronic hepatitis C[J]. Eur J Gastroenterol Hepatol, 2020, 32(4): 524-527.
[52] Ding Q M, Zhou W Q, Mao W L, et al. Mean platelet volume/platelet count ratio as a predictor of 3-month mortality in HBV-related decompensated cirrhosis patients[J]. Clin Lab, 2020, 66(3) :10.7754.

血小板与肝硬化相关性研究进展

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	孙成林, 王冰琼, 孙亚朦, 尤红. 肝硬化门静脉高压的无创诊断及预后评估新进展[J]. 肝脏, 2025, 30(6): 756-758.
[2]	冯仕川, 沈勇. GLUT-1、CDK4与原发性肝癌患者临床病理特征和预后关系分析[J]. 肝脏, 2025, 30(6): 773-776.
[3]	魏丽, 施文娟, 周晓丽, 杨学芳, 马海文, 万红. 免疫炎症指标与HBV相关慢加急性肝衰竭患者预后的相关性[J]. 肝脏, 2025, 30(6): 793-795.
[4]	俞媛, 张丹丹, 包薇萍, 褚晓秋, 窦英磊, 张美云. NLR对NAFLD患者预后预测价值的Meta分析[J]. 肝脏, 2025, 30(6): 813-819.
[5]	董晓锋, 梁栋. 麻疹合并肝生化指标异常的回顾性分析[J]. 肝脏, 2025, 30(6): 850-851.
[6]	李光林, 李恒, 程勋, 杨贵彬, 罗大勇. C反应蛋白/白蛋白比值联合血小板与淋巴细胞比值预测恶性梗阻性黄疸介入治疗患者预后的价值[J]. 肝脏, 2025, 30(6): 862-867.
[7]	李雨蓉, 邵思锦, 韦陆霏, 薛添奕, 王杰. 非侵入性检测在评估肝功能失代偿中的应用[J]. 肝脏, 2025, 30(5): 582-584.
[8]	张艳, 温青萍, 钱花, 石荔. 富马酸丙酚替诺福韦联合扶正化瘀片治疗乙型肝炎肝硬化代偿期患者的临床效果[J]. 肝脏, 2025, 30(5): 595-598.
[9]	沈雯雯, 赵丹丹, 苗晗, 嵇海艳. 血清维生素B12、β-抑制蛋白2表达与肝硬化上消化道出血患者病情严重程度和预后的相关性[J]. 肝脏, 2025, 30(5): 599-603.
[10]	刘佳, 刘艳, 陈晋. 肝硬化门静脉高压脾功能亢进患者腹腔镜脾切除术后门静脉系统血栓形成的危险因素[J]. 肝脏, 2025, 30(5): 604-608.
[11]	周秀梅, 刘慧, 王时军. 高频超声联合声触诊弹性成像诊断肝硬化不同时期的价值分析[J]. 肝脏, 2025, 30(5): 609-612.
[12]	张志博, 李静, 邱婧琪, 王倩, 梁爽, 刘翠翠. 超声内镜检查诊断乙型肝炎肝硬化患者食管胃底静脉曲张的价值及对EVL治疗效果的评价[J]. 肝脏, 2025, 30(5): 613-616.
[13]	解维敏, 刘杰. 乙型肝炎肝硬化及原发性肝癌患者血清铁蛋白、Hcy、维生素B12的表达[J]. 肝脏, 2025, 30(5): 630-632.
[14]	万芝清, 王权, 孙静, 常小云, 张爱民, 李文刚, 段学章. 立体定向放射治疗大肝癌的疗效[J]. 肝脏, 2025, 30(4): 431-434.
[15]	张粉娜, 张心怡, 孙荣荣, 郝帅, 王辉, 贺娜, 钟岳. RNA结合蛋白SMG5与肝癌临床病理及免疫浸润相关性分析[J]. 肝脏, 2025, 30(4): 435-440.